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Background: Human T-cell lymphotropic virus (HTLV-1) is the causative agent of the incapacitating, neuroinflammatory
disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Currently, there are no disease-modifying
therapies with long-term clinical benefits or validated biomarkers for clinical follow-up in HAM/TSP. Although CD80 and
CD86 costimulatory molecules play prominent roles in immune regulation and reflect disease status in multiple sclerosis
(MS), data in HAM/TSP are lacking.
Methods: Using flow cytometry, we quantified ex vivo and in vitro expression of CD80 and CD86 in PBMCs of healthy
controls, HTLV-1-infected individuals with and without HAM/TSP, and MS patients. We hypothesized ex vivo CD80 and
CD86 expressions and their in vitro regulation by interferon (IFN)-α/β mirror similarities between HAM/TSP and MS and
hence might reveal clinically useful biomarkers in HAM/TSP.
Results: Ex vivo expression of CD80 and CD86 in T and B cells increased in all HTLV-1 infected individuals, but with a
selective defect for B cell CD86 upregulation in HAM/TSP. Despite decreased total B cells with increasing disease
duration (p = 0.0003, r = −0.72), CD80+ B cells positively correlated with disease severity (p = 0.0017, r = 0.69) in HAM/TSP.
B cell CD80 expression was higher in women with HAM/TSP, underscoring that immune markers can reflect the
female predominance observed in most autoimmune diseases. In contrast to MS patients, CD80+ (p = 0.0001) and
CD86+ (p = 0.0054) lymphocytes expanded upon in vitro culture in HAM/TSP patients. The expansion of CD80+
and CD86+ T cells but not B cells was associated with increased proliferation in HTLV-1 infection. In vitro treatment with
IFN-β but not IFN-α resulted in a pronounced increase of B cell CD86 expression in healthy controls, as well as in
patients with neuroinflammatory disease (HAM/TSP and MS), similar to in vivo treatment in MS.
Conclusions: We propose two novel biomarkers, ex vivo CD80+ B cells positively correlating to disease severity and
CD86+ B cells preferentially induced by IFN-β, which restores defective upregulation in HAM/TSP. This study suggests a
role for B cells in HAM/TSP pathogenesis and opens avenues to B cell targeting (with proven clinical benefit in MS) in
HAM/TSP but also CD80-directed immunotherapy, unprecedented in both HAM/TSP and MS.
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Human T-cell lymphotropic virus 1 (HTLV-1) was the
first human retrovirus to be isolated [1]. In contrast to
HIV, the provirus preferentially replicates through oligo-
clonal proliferation of infected cells rather than by new
virion production [2]. Although estimates suggest that
about 10–20 million people worldwide are HTLV-1 sero-
positive [3], a recent review by Hlela et al. suggests that
this number could be underestimated [4]. While most of
the HTLV-1 seropositive individuals remain asymptom-
atic lifelong, a minority of HTLV-1-infected individuals
progress to severe, often fatal disease [5]. The more pre-
dominant complications are adult T-cell leukemia/lymph-
oma (ATL) and HTLV-1-associated myelopathy/tropical
spastic paraparesis (HAM/TSP) [5]. This disparity in dis-
ease outcome is still not well understood, but is probably
determined by the interaction between viral, immune and
host genetic factors [6].
HAM/TSP is a chronic progressive inflammatory dis-
order causing degenerative myelopathy. It evolves pro-
gressively from inception, with spastic paraparesis or
paraplegia being the principal clinical condition, accom-
panied by bladder dysfunction and sensory deficit in the
lower extremities [5]. The impact of disease severity is
presented by two commonly used scales: Kurtzke’s
Expanded Disability Status Score (EDSS) [7] and the
Osame Motor Disability Score (OMDS) [8]. Given that
the host’s immune system is generally considered re-
sponsible for inflicting inflammatory damage to the
spinal cord [9], various therapeutic approaches, mostly
immunomodulators and antivirals, have been adopted in
HAM/TSP. Corticosteroids such as prednisolone and
hydrocortisone as well as the immunomodulatory cyto-
kine interferon (IFN)-α have shown some clinical benefit
[10]. However, effective or disease-modifying therapy is
still unavailable [11], as are bona fide biomarkers for dis-
ease progression and/or therapeutic failure. Proviral load
is currently the most widely used biomarker in HAM/
TSP research, although it did not reflect therapeutic
response in recent clinical trials using antiretrovirals,
valproic acid, or IFN-α or IFN-β [12-15].
An increased T-cell activation, uncontrolled lymphocyte
proliferation [16] and proinflammatory cytokine produc-
tion in HTLV-1-infected subjects have been associated
with the development of disease [17]. Ex vivo findings in-
clude high proviral load in peripheral blood mononuclear
cells (PBMCs) [18] and proinflammatory cytokines such
as tumor necrosis factor (TNF)-α, interleukin (IL)-6 and
IFN-γ in the serum and cerebrospinal fluid (CSF) [19-21].
Neuropathological analysis revealed T cell (CD4+ and
CD8+) dominant, mononuclear cell infiltration [9]. In
addition to preferential infection of T cells, the virus is also
known to infect antigen-presenting cells (APCs), namely
dendritic cells, B cells and macrophages, which regulateT cell fate in vivo [22,23]. An inflammatory process de-
pends on T cell activation, which requires engagement of
the T cell receptor (TCR) with the MHC-peptidecomplex
presented on the cell surface of APCs. In addition to this
antigen-specific stimulation, a second interaction involving
a costimulatory molecule, CD28, on T cells and its ligands,
CD80 (B7.1) and CD86 (B7.2), on APCs is required for op-
timal T cell activation [24]. Further, these two signals do
not need to be delivered concomitantly for optimum T cell
activation [25]. In HAM/TSP patients, costimulatory mole-
cules on APCs induced by viral tax provide constant anti-
gen presentation and costimulation to T cells, leading to
intense T cell proliferation and inflammatory responses
[26]. Interestingly, expression of CD80 and CD86 is not re-
stricted to APCs, but may be expressed in T cells of
HTLV-1-infected individuals [27]. The use of anti-CD80
and anti-CD86 antibodies inhibited spontaneous prolifera-
tion of lymphocytes. In addition, simultaneous addition of
anti-CD80 and anti-CD86 antibodies inhibited production
of IFN-γ, TNF-α and IL-4, with no effect on IL-10 produc-
tion for both, allo- and autologous T cell proliferation.
Taken together, these results suggest that HTLV-infected
CD80+/CD86+ T cells could also serve as APCs, enabling a
sustained proliferation of T cells [26].
In EAE, a mouse model for MS, the blocking of the
costimulatory molecules CD80 and CD86 in peripheral
blood cells and the use of CD80/CD86 knockout mice
provide evidence of their pathogenic role [28-30]. Inter-
estingly, even reactive astrocytes may potentially share
the functions of APCs given their expression of CD80
and CD86 [31]. While data are lacking on the expression
of CD80 and CD86 in HTLV-1 infection and pathogen-
esis, IFN-α enhanced CD80 expression in vitro in mye-
loid leukemia [32], while IFN-β has been shown to
regulate CD80 and CD86 in vivo and in vitro in MS
[33,34]. IFN-β treatment also reduced CD80-induced IL-2
producing cells in vitro [35]. Taken as a whole, modulation
of CD80 and CD86 costimulatory molecules occurs in dif-
ferent cell types and is postulated to participate in MS
pathogenesis.
In addition, in MS, IFN-β, one of the current first-line
therapies [36], has been effective in numerous therapeutic
trials and has been widely used in the last 2 decades [37,38].
In HAM/TSP, both IFNs have been tested in only a few
therapeutic trials [10,14,15,39,40], while their mechanism of
action remains enigmatic. We hypothesized that ex vivo ex-
pression of CD80 and CD86 as well as the in vitro effects of
IFN-α and IFN-β on their expression could reveal bio-
markers for possible clinical use in HAM/TSP.
Patients and methods
Sampling
This study was approved by the Ethics Committee of the
Oswaldo Cruz Foundation (FIOCRUZ), Salvador-Bahia,
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Peru, and Hôpital La Pitié-Salpêtrière, Paris, France. A
total of 55 individuals, including 23 healthy controls
(HCs), 6 HTLV-1-infected individuals without HAM/
TSP (asymptomatic carriers, ACs) and 26 HAM/TSP pa-
tients (9 men and 17 women) were recruited from two
endemic regions (Salvador-Bahia, NortheEast Brazil, and
Lima, Peru) following written informed consent. HAM/
TSP was diagnosed by the Osame criteria (based on
WHO guidelines) [41]. Antibodies to HTLV-I/II were in-
vestigated by diagnostic enzyme-linked immunosorbent
assay (ELISA, Cambridge Biotech, Worcester, MA, USA)
and confirmed by Western blot capable of discriminat-
ing between HTLV-I and HTLV-II (HTLV Blot 2.4,
Genelab, Singapore; Abott Diagnostics, USA; Murex
Diagnostics, UK, or Biokit, Spain). Proviral load (which
is the viral DNA integrated in the host cellular genome)
in HAM/TSP patients and ACs was quantified according
to Grassi et al. in Brazil [42] and Adaui et al. in Peru
[43]. In the MS cohort, 20 patients with relapsing/remit-
ting MS, 5of whom had stable disease, analyzed at base-
line and 1 month after in vivo treatment with IFN-β1a
(30 μg administered intramuscularly, once weekly), were
recruited at Hôpital La Pitié-Salpêtrière, Paris, France,
following provision of written informed consent.
Cell culture
PBMCs were obtained from 5-10 ml of heparinized
venous blood by passage over a Ficoll Hypaque gradient
(Sigma-Aldrich). PBMCs were washed twice with PBS
and resuspended at a concentration of 4 × 106 cells/ml
in RPMI1640 medium supplemented with 2 mM L-
glutamine, gentamycin (50 μg/ml) and 10% heat-
inactivated fetal calf serum (all fromLife Technologies,
NY). Cells were plated in 24-well tissue culture platesCD
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Figure 1 Gating strategy for CD80 and CD86 quantification in PBMCs
CD3-, CD19-, CD80- and CD86-specific monoclonal antibodies and analyzed
gate. Percentages of CD80+ and CD86+ cells within the lymphocyte gate (P(Costar, Corning Incorporated, NY) at a concentration
of 4 × 106 cells/ml and incubated at 37°C and 5% CO2.
In vitro stimulation was performed by addition of IFN-
α2a (1,000 U/ml) or IFN-β1b (1,000 U/ml), or anti-CD3
as a positive control. Cells were collected at 48 h and
stained for flow cytometry.
Flow cytometry
For phenotypic analyses, PBMCs were resuspended at a
density of 200,000 cells in 50 μl of 1% BSA plus 0.1% so-
dium azide in PBS and incubated for 30 min on ice with
mAbs specific for CD3, CD4, CD8, CD19, CD80, CD86
and the corresponding isotype controls (BD Biosciences).
A minimum of 10,000 events per sample was acquired
with FACSort and FACS CantoII flow cytometers (BD
Biosciences) and analyzed using CellQuest and Diva
software, respectively. Figure 1 shows dot plots of a rep-
resentative HAM/TSP patient to indicate the gating
strategy for CD80 and CD86 quantification in B and T
cells. For proliferation analysis, after 48 h of in vitro cul-
ture, PBMCs were stained with the antibody cocktail (listed
above) and Hoechst 33342 and incubated for 15 min in the
dark at room temperature before acquisition. Proliferat-
ing (tetraploid, 4n) lymphocytes were quantified in spe-
cific (CD80+ and CD86+ T and B cell) gates based on
MFI of Hoechst 33342, which is twice that of the dip-
loid (2n) gate, representing lymphocytes with normal
DNA content. Doublets (gated using width vs. area dot
plots) and sub-diploid/apoptotic cells (gated using
DNA content vs. side scatter) were excluded.
Statistical analysis
The use of parametric versus non-parametric tests was
decided based upon the Kolmogorov-Smirnov test for
normality. These included paired and unpaired t test,CD80 CD86
. PBMCs from a representative HAM/TSP patient were stained with
by flow cytometry. P1 (in blue contours) represents the lymphocyte
1) are indicated in the respective quadrants (red contours).
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comparison test or Kruskal-Wallis test with Dunn’s
post test, Spearman’s correlation analysis and receiver-
operator characteristic (ROC) curve analysis. All tests
were two-tailed, and differences were considered sig-
nificant at p values <0.05.HC AC HAM/TSP HC AC HAM/TSP
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Clinical and demographic data
All HTLV-1 infected individuals were serologically posi-
tive for HTLV-1 and negative for HTLV-2. The median
proviral load was 2,782 copies/104 PBMCs (range: 6.3–
3,805 copies/104 PBMCs).
The mean age of HAM/TSP patients was 49.5 ± 2.1
years (range: 27–64 years) and mean duration of disease
was 7.0 ± 1 years (range: 0.8–20 years). EDSS ranged
from 3–7 (mean 4.8 ± 0.3). For a subgroup of Brazilian
patients, the Osame Motor Disability Scale was also avail-
able. We observed a significant positive correlation between
Kurtzke’s EDSS score and the Osame score (p = 0.001,
r = 0.81, n = 12), similar to the findings of Olindo et al.
in a group of 100 patients from the French WestIndies
[44]. The mean age of HCs was 33.9 ± 3.8 years (range
23.6–43.8 years), while that of ACs was 40 ± 7.8 years
(range 9–64 years).HC AC HAM/TSP HC AC HAM/TSP
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Figure 2 Increased ex vivo expression of CD80 and CD86 in T
and B cells of HAM/TSP patients and HTLV-1 asymptomatic
carriers (ACs). CD80 and CD86 expression in (A) T (CD3+) cells and (B) B
(CD19+) cells of HCs (n = 15), ACs (n = 6) and HAM/TSP patients (n = 21)
were quantified using flow cytometry. (*p < 0.05, **p < 0.01, ***p < 0.001;
Kruskal-Wallis test with Dunn’s multiple comparison post test).Increased ex vivo frequency of CD80+ and CD86+
lymphocytes in HTLV-1-infected individuals and selective
loss of B cell CD86 upregulation in HAM/TSP patients
We quantified the surface expression of CD80 and CD86
in T and B lymphocytes in HCs (n = 15), ACs (n = 6) and
HAM/TSP patients (n = 21) by flow cytometry. As shown
in Figure 2, we observed a significant increase in the per-
centage of ex vivo CD80+ T cells (CD3+CD19-) as well as
CD86+ T cells between infected and uninfected subjects.
Furthermore, CD80+ B cells (CD3-CD19+) were signifi-
cantly enhanced in HTLV-1-infected individuals when
compared to HCs. Interestingly, there was a significant in-
crease in CD86+ B cells only in ACs but not in HAM/TSP
patients when compared to HCs, indicating a selective loss
in HTLV-1 upregulation of B cell CD86 upon disease pro-
gression to HAM/TSP. However, expression of CD80 and
CD86 on a per-cell basis, as mean fluorescence intensity
(MFI), did not differ significantly among HCs, ACs and
patients in either cell type (data not shown).
In addition, in HAM/TSP patients, we observed a
positive correlation between the ex vivo expression of
CD80 and CD86 in T cells (p = 0.039, r = 0.50, n = 18)
but not in B cells (p > 0.05,n = 17) (data not shown). This
implies that CD80 and CD86 expression may be differ-
entially regulated in HAM/TSP only, since there was no
significant correlation in ex vivo expression of CD80 and
CD86 in any cell type in HCs and ACs (data not shown).CD80+ B cell expression is positively correlated to disease
severity and is gender biased in HAM/TSP patients
To explore the possible clinical relevance of increased
CD80 and CD86 on B and T cells, we correlated flow
cytometry results to clinical and demographic patient
data. We observed that the percentage (but not MFI) of
CD80-expressing B cells but not CD80-expressing T
cells or total lymphocytes positively correlated with dis-
ease severity as measured by Kurtzke’s EDSS (r = 0.73,
n = 18) (Figure 3A). Expression of CD86 (either as % or
as MFI) in B or T cells as well as total lymphocytes did
not correlate to disease severity (data not shown). Interest-
ingly, the ratio of CD86:CD80 expression in B cells but
not in T cells correlated negatively to disease severity in
HAM/TSP patients (r = −0.50, n = 18) (Additional file 1:
Figure S1), implying a possible antagonism between the
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Figure 3 Ex vivo levels of CD80+ B cells correlate with disease
severity, whereas total B cell (CD19+) levels decrease overtime in
HAM/TSP patients. (A) Positive correlation between the percentage of
CD80 in B cells (CD19+) and Kurtzke’s EDSS. (***p= 0.0006, Spearman’s
r= 0.73, n= 18). (B) Ex vivo CD19+ B cell level is negatively correlated to
disease duration in HAM/TSP patients (n= 21). (***p= 0.0003, Spearman’s
r= 0.72, n= 21). 0.01
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Figure 4 Increased ex vivo expression of CD80 in B cells of
MS patients. MS patients with active disease (n = 6) expressed
significantly higher levels of CD19+CD80+ than MS patients with
non-active disease (n = 10), and both groups were higher in
CD19+CD80+ expression than HCs (n = 15). (*p < 0.05, ***p < 0.001;
ANOVA with Bonferroni’s multiple comparison post test).
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Genç et al. in MS patients [33]. Further, the percentage of
total CD19+ B cells negatively correlated to disease dur-
ation (r = −0.72) (Figure 3B) but not to age or EDSS. Not-
ably, proviral load, disease duration and age did not
correlate to disease severity (data not shown). Therefore,
the increase in CD80 expression in B cells in HAM/TSPpatients, which occurs despite a decrease in total B cell
levels, likely reflects disease progression rather than
prolonged infection or disease duration. Our findings
in HAM/TSP patients are highly similar to those in MS
patients. We observed a significant increase in CD80
expression in B cells of MS patients with both active
and non-active disease as compared to HCs (Figure 4),
in agreement with Genç et al. [33]. Given the decrease
in total B cell levels in HAM/TSP patients (Figure 3B),
we used relative CD80 B cell expression (CD80+:CD19+ ra-
tio) in HAM/TSP and absolute values of CD80-expressing
B cells (CD19+CD80+) in MS. Using receiver-operating
characteristic (ROC) curves, we found that the CD80+:
CD19+ ratio and CD19+CD80+ levels could discrimin-
ate between patients with impaired mobility in HAM/
TSP (p = 0.0010, AUC = 0.96) and patients with active
MS (p = 0.0077, AUC = 0.88), respectively. The best
performing cutoffs were 0.23 for the CD80+:CD19+ ra-
tio and 8.4% for CD19+CD80+, respectively (Additional
file 2: Figure S2 A, B).
In addition, the percentage of CD80+ B cells but not
CD80+ T cells or CD80+ total lymphocytes was significantly
higher (2.3 fold) in female (n = 14) versus male (n = 7) pa-
tients (Figure 5A), whereas CD86 expression was not
significantly different between female and male patients
in any lymphocyte population (Figure 5A and data not
shown). There is a predominance of HAM/TSP in
women [45], who were also found to have more severe
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Figure 5 Gender-biased expression of CD80 but not CD86 in
B cells of HAM/TSP patients. (A) Expression of CD80 but not CD86
in B cells is increased in female (n = 14) versus male (n = 7) patients
(**p = 0.0013, unpaired t test). (B) B cell CD80 expression corrected
for disease severity (EDSS) is significantly higher in female (n = 12)
versus male (n = 6) HAM/TSP patients. (**p = 0.0054, unpaired t test).
Figure 6 Expansion of CD80+and CD86+ lymphocytes upon
in vitro culture of PBMCs of HAM/TSP patients but not in HTLV-1
carriers and MS patients. CD80 and CD86 expression in PBMCs was
quantified before (ex vivo) and after 48 h of in vitro culture by flow
cytometry. (A) Significant in vitro expansion of CD80+ cells in
HAM/TSP patients (***p = 0.0001, n = 12) and HCs (*p = 0.049,
n = 6). (B) Significant in vitro expansion of CD86+ cells in HAM/TSP
patients only (**p = 0.0054; paired t test).
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ation of CD80+ B cells with both female gender and
disease severity was not interdependent. As shown in
Figure 5B, CD80+ B cell levels corrected for EDSS were
still significantly higher in female vs. male HAM/TSP
patients (p = 0.0054, unpaired t test). It would be inter-
esting to confirm these findings in HAM/TSP patients
of other endemic regions as well as in large MS
cohorts.
CD80+ and CD86+ lymphocytes expand upon in vitro
culture in HAM/TSP but not MS patients
The decrease in ex vivo total CD19+ B cells in HAM/
TSP patients over time (Figure 3B) somehow contrasts
with the observed ex vivo increase in CD80+ B cells.
Hence, increased CD80 levels in B cells could be due to
proliferation of a specific B cell subset in HAM/TSP.
Low but detectable proliferation of total B cells has been
demonstrated in vitro for HAM/TSP patients [47,48], al-
beit significantly lower than that of CD8, CD4 or NKcells [47]. Therefore, we examined the effect of in vitro
culture upon CD80 and CD86 expression as compared
to ex vivo levels.
As shown in Figure 6A and B, in HAM/TSP patients,
at 48 h of in vitro culture, we observed a significant (2.2-
fold) increase in CD80+ lymphocytes and a significant
(3.2-fold) increase in CD86+ lymphocytes versus ex vivo
levels. In contrast, only CD80, but not CD86, expression
in HCs (and neither CD80 nor CD86 expression in ACs)
was increased upon in vitro culture. However, the ratio
of CD86:CD80 in HCs, ACs and HAM/TSP patients did
not alter significantly upon in vitro culture (data not
shown). In both HCs and HAM/TSP patients, B cells
were the main in vitro reservoir of CD80+ and CD86+
lymphocytes (data not shown), in agreement with previ-
ous results observed by Genç et al. in MS patients and
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CD80+ and CD86+ lymphocytes in HAM/TSP, we inves-
tigated whether a similar phenomenon occurred in MS.
However, there was no significant expansion in either
the percentage or MFI of CD80 or CD86 in either B cells
or total lymphocytes upon in vitro culture of PBMCs of
MS patients (Figure 6A and B). As such, in vitro expan-
sion of these subpopulations is not common to neuroin-
flammatory diseases but rather a HAM/TSP-specific
phenomenon. Regarding the role of the virus, the
in vitro increase in CD80+ T cells (but not CD86+ T or
CD80+/CD86+ B cells) was significantly correlated to
the proviral load in both HTLV-1 infected individuals
(p = 0.013, Spearman’s r = 0.66, n = 13) and HAM/TSP
patients (p = 0.0046, Spearman’s r = 0.91, n = 8). InDN
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Figure 7 Increased proliferation of CD80+ and CD86+ T cell subsets b
(A) PBMCs were cultivated in vitro for 48 h, and anti-CD3, anti-CD19, anti-C
quantified using flow cytometry. Tetraploid (4n, proliferating) cells were ga
B (CD3-CD19+) cells. (B,C) Proliferating CD80+ T cells were significantly incr
significantly increased in ACs vs. HCs only (B), whereas there was no signifi
and n = 5 for ACs and HAM/TSP patients, Kruskal-Wallis with Dunn’s multipcontrast, spontaneous lymphoproliferation in HAM/
TSP patients, as measured by [3H]-thymidine incorpor-
ation, was positively correlated to all four lymphocyte
subsets, i.e., CD80+ and CD86+ T and B lymphocytes
(data not shown). Therefore, we analyzed specific T and
B cell subsets for short-term (48-h) spontaneous prolif-
eration using a sensitive flow cytometric assay. This
short-term assay allowed simultaneous, single-cell ana-
lysis of CD80, CD86 and proliferation in both B and T
cells (Figure 7A) and also eliminated the possible bias of
selective B or T cell apoptosis during long-term (5-day)
in vitro culture using [3H]-thymidine incorporation. As
shown in Figure 7B, proliferation of the CD80+ T cell
subset in HAM/TSP patients, but not in ACs, was sig-
nificantly higher than in HCs. On the other hand,19+)  CD86+ 
19-)  CD86+ 
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Figure 8 Expression of CD80 and CD86 as MFI in B cells of
HAM/TSP patients and HCs following in vitro treatment with
IFN-α and IFN-β. (A,B) IFN-β but not IFN-α enhanced expression of
CD86 in B cells in both (A) HCs (**p = 0.0070, n = 10) and (B) HAM/
TSP patients, (*p = 0.023, n = 8). (*p < 0.05, **p < 0.01, ***p < 0.001;
ANOVA with Bonferroni’s multiple comparison post test).
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in patients, was significantly higher than in HCs. This
once more suggests a differential, i.e., deleterious vs.
protective, regulation of both costimulatory molecules.
We found no significant difference in proliferation of
CD80+ or CD86+ B cell subsets between HCs, ACs and
HAM/TSP patients (Figure 7C). Taken together, these
results imply that increased ex vivo T cell CD80 and
CD86 expression (Figure 2A) reflects increased prolifer-
ation of CD80+/CD86+ T cell subsets, whereas in-
creased ex vivo B cell CD80 expression in both HTLV-1
infected individuals and HAM/TSP patients (Figure 2B)
is probably not mediated by increased proliferation of
the CD80+ B cell subset.
IFN-β preferentially stimulates B cell CD86 expression in
HCs and HAM/TSP patients
In both HCs and HAM/TSP patients, percentages of
CD80+ or CD86+ total lymphocytes as well as T and B
cells did not increase significantly on treatment with
IFN-α or IFN-β (data not shown), whereas the increase
in MFI was more pronounced. As shown in Figure 8A
and B, stimulation with IFN-α or IFN-β was unable to
significantly modulate CD80+ B lymphocyte expression
(MFI) in HCs as well as in HAM/TSP patients. On the
other hand, IFN-β but not IFN-α significantly enhanced
CD86 B lymphocyte expression (MFI) in both HCs and
HAM/TSP patients. Upon IFN-β stimulation, the induc-
tion of CD86 expression (MFI) was comparable in both
groups, namely HCs (1.9 fold) and HAM/TSP patients
(2.2 fold). Similarly, in both groups the HCs and HAM/
TSP patients, there was a significant increase in the ratio
of CD86:CDs80 in B lymphocytes with IFN-β (p = 0.011
and p = 0.019, respectively) with a similar fold increase
(1.6 fold and 1.7 fold, respectively). No significant in-
crease was observed in the ratio for IFN-α in either HCs
or HAM/TSP patients (p > 0.20 for both, data not
shown).
To investigate the in vivo relevance of our in vitro data,
we compared the in vivo and in vitro effect of IFN-β in
MS patients. In keeping with Genc et al. [33,49], after
1 month of in vivo treatment with IFN-β, we observed
a 1.72-fold decrease in the percentage of CD80+ B
lymphocytes (p = 0.089) and a 1.5-fold increase in the
percentage of CD86+ B lymphocytes (p < 0.0001) but
not in total lymphocytes. In addition, upon in vitro
treatment with IFN-β, the percentage of CD80+ B lym-
phocytes was downregulated in five of six MS patients
(p < 0.0001), while the CD86+ B lymphocyte level was
highly variable (data not shown), similar to the observa-
tions of Ramgolam et al. [50]. Thus, both in vivo and
in vitro IFN-β treatment can decrease CD19+CD80+
and increase CD19+CD86+ B cells in MS patients, but
with a strikingly high inter-patient variability consistentwith previous studies [33,50]. Given this strong inter-
patient variability, we recalculated IFN stimulation as %
of control baseline values (MFI IFN-stimulated:MFI un-
stimulated cells) to enable a direct comparison between
patient groups. We observed a highly similar in vitro
response (mean % increase ± SEM) to IFN-β for CD80,
CD86 and another IFN-regulated (Rep et al., 1999; Van
Weyenbergh et al., 2001) surface molecule (Fas/CD95,
data not shown) in both HAM/TSP and MS patients.
This reveals that, despite immune dysregulation in pa-
tients with neuroinflammatory disease, the immuno-
modulatory potential of IFN-β is unaltered.
Discussion
Until now, there have been no validated biomarkers for
clinical monitoring of HAM/TSP patients for either dis-
ease progression or therapeutic response to any of the
drugs currently used. The biomarkers proposed thus far
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in proviral load and viral tax mRNA) or remain to be
validated in other cohorts, namely viral HBZ mRNA
[51] and host CD4+CD25+CCR4+Foxp3-IFN-γ+ T cells
[52]. We hypothesized that ex vivo expression of CD80
and CD86 as well as the in vitro effects of IFN-α and
IFN-β on their expression could reveal biomarkers for
possible clinical use in HAM/TSP. In this study, which is
the first to recruit HAM/TSP patients from two endemic
countries (Brazil and Peru), we reveal CD80+ B cells as a
novel host biomarker for disease severity (Figure 3A),
while highlighting a possible protective role for CD86+ B
cells, which are preferentially upregulated by IFN-β in
HAM/TSP, both uncorrelated to proviral load.
B cell-expressed CD80/CD86 has been shown to drive
pathogenesis in autoimmunity [53-55]. Despite their
largely overlapping functions in T cell activation and im-
mune upregulation in autoimmunity [28], CD80 and
CD86 on APCs also play additional individually distinct
roles, which cannot be substituted for by the other
[56,57]. In murine models of graft arterial disease [58]
and sepsis [59], CD80 is associated with proinflamma-
tory cytokine stimulation, while CD86 plays a protective
role mediated through IL-4 [58] or IL-10 [60] produc-
tion. Further, CD80 and CD86 are differentially regu-
lated in different tissue compartments [54,61] as well as
cell types ([33], this study). Given the increase in CD80+
B cells in the CSF of MS patients [62,63], migration of
CD80+ B cells from peripheral blood into the CNS is an
intriguing possibility in HAM/TSP. In MS patients, in-
creased B cell CD80 expression corresponds to exacer-
bations [33], and pronounced expression of CD80 i has
been demonstrated in early active plaques [64]. In
addition, a recent genome-wide association study impli-
cated CD80, but more strongly CD86, in MS susceptibil-
ity [65]. CD80 is thought to play a key role in persistent
infections or chronic inflammatory conditions [66],
while CD86 plays a dominant role in initiating immune
reactions [67]. Although not demonstrated in HTLV-1
infected patients, a positive correlation between spon-
taneous lymphoproliferation and CD80 expression was
observed in HTLV-2-infected patients [26], indicating a
possible mechanism for simultaneous upregulation of
both deleterious candidate biomarkers, IFN-γ [52] and
CD80 [this study], in HAM/TSP pathogenesis. Among
other cytokines, proinflammatory IFN-γ transcripts are
upregulated in HAM/TSP patients and seropositive car-
riers when compared to HCs [68]. In vitro studies in
PBMCs of HAM/TSP patients and HTLV-1 carriers have
indicated that drugs targeting TNF-α resulted in con-
comitant lowering of IFN-γ [69], implying that a com-
mon mechanism, at least in part, regulates the two
cytokines. As discussed by Moens et al., miR-155 could
serve as a candidate molecule to modulate IFN-γproduction in HAM/TSP patients in parallel to its
pathogenic role in MS and EAE [70]. In MS, endogenous
IFN-γ significantly correlates to disability [71], and ex-
ogenous IFN-γ causes disease exacerbation [72]. Block-
ing B7-mediated activation causes long-term inhibition
in EAE [73]. More specifically, blocking of CD80 inhibits
EAE, while blocking of CD86 may even aggravate disease
[29,55]. Finally, only CD80 interacts with PD-L1, which is
required for the maintenance of peripheral T cell tolerance
[74] and participates in EAE pathogenesis [75]. Taken to-
gether, in both autoimmune and infectious diseases a sub-
stantial amount of data is available on the differential
regulation of CD80 vs. CD86, supporting our hypothesis
of deleterious and protective roles for CD80+ and CD86+
B cells, respectively, in HAM/TSP pathogenesis.
Two possible mechanisms might be responsible for
the observed differential expression of CD80/CD86 in B
cells, either de novo synthesis induced by host transcrip-
tion factors and/or viral transactivator tax and HBZ or a
selective proliferation of CD80+ vs. CD86+ B cells. Some
of the principal players among host transcriptional fac-
tors are interferon regulatory factor (IRF)-1, nuclear fac-
tor (NF)-κB, and signal transducer and activator of
transcription (STAT)-1. IRF-1 [32] as well as NF-κB [76]
exert transcriptional control in upregulating CD80. In-
creased proinflammatory IFN-γ is capable of inducing
IRF-1 directly or via STAT-1 [77]. Further, IFN-γ is cap-
able of a five-fold induction of STAT-1 and IRF-1 in B
cells [78], while stimuli such as TNF activating the NF-κB
pathway [79,80] could account for CD80 upregulation. On
the other hand, the CD86 gene promoter contains two
STAT-1 binding sites, which might explain its upregula-
tion by IFNs [81]. We therefore hypothesize a relationship
between the two host cell biomarkers associated with
HAM/TSP disease severity: CD4+CD25+CCR4+Foxp3-
IFN-γ+ [52] and CD19+CD80+ cells (this study). It is
plausible that CD4+CD25+CCR4+Foxp3-IFN-γ+ cells
could influence the upregulation of CD80 in B cells
through IFN-γ stimulation. In MS, it has been shown
that endogenous IFN-γ significantly correlates to dis-
ability [71] and exogenous IFN-γ causes disease exacer-
bation [82].
As shown in Figure 9, we propose a scheme integrat-
ing the proposed viral and host biomarkers for HAM/
TSP disease severity that might help explain differential
CD80 and CD86 expression. The regulation and inter-
play between these host factors could be driven by viral
tax or HBZ. Although data on the role of HBZ in HAM/
TSP have been scarce, Saito et al. recently demonstrated
a positive correlation between HBZ mRNA and disease
severity [51]. This increase in the HBZ mRNA level
could likely entail an increase in HBZ protein, either of
which may be involved in HAM/TSP pathogenesis based
upon their differential role in ATL [83]. On the other
Figure 9 Proposed model integrating viral and host biomarkers for disease severity and the effect of IFN-β in HAM/TSP. Viral tax could
be driving the upregulation of CD80-expressing B cells in an IFN-γ/IRF-1 [77,78] or TNF/NF-κB [79,80,84] dependent manner. HBZ downregulates
tax [103] and the NF-κB pathway [104], thereby possibly downregulating CD80 expression. IFN-γ-producing CD4+CD25+CCR4+Foxp3- host cells
[52] could positively influence CD80 expression in a STAT-1/IRF-1-dependent manner. IFN-β induced downregulation of CD80 expression in B cells
[33] could be, in part, due to its antagonistic effect on IFN-γ [100-102] as well as modulation of cytokines (IL-10 and IL-12) [105,106] regulating
IFN-γ. CD86 expression by IFN-β may be driven via STAT-1 or possibly via IL-10. HTLV-1-infected pDCs produce endogenous IFN-α [91], which
might upregulate B cell CD86 expression in vivo. The continuous arrows and inhibition lines indicate published data, while the discontinuous
lines indicate hypothetical links drawn from this study. The proinflammatory molecules/cells are in shades of brown/red, while anti-inflammatory
molecules/cells are in shades of green. Proposed biomarkers for HAM/TSP are enclosed in boxes.
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tion [84]. Tax contributes greatly to inflammatory reac-
tions related to the CNS because of the overexpression of
TNF-α and IFN-γ [85-87]. The increase in CD80+ B cells
could thus be driven by tax in an IFN-γ/IRF-1- or TNF-α/
NF-κB-dependent manner. Therefore, it would be inter-
esting to determine whether CD4+CD25+CCR4+Foxp3-
IFN-γ+ cells could be (a subset of) the T cells expressing
CD80 or CD86, given their role in EAE [88]. We found
that in vitro proliferation of HAM/TSP PBMCs positively
correlates to both CD80+CD3+ and CD86+CD3+ cells
(Van Weyenbergh et al., unpublished data). However,
since neither CD80+ nor CD86+ T cells correlated to dis-
ease severity, the CD4+CD25+CCR4+Foxp3-IFN-γ+ cells
are probably a distinct T cell population. Given that B cells
proliferate to a lesser extent than T and NK cells [47], the
observed increase in CD80/CD86 expression in B cells
might be due to de novo expression rather than B cell
proliferation, as suggested by Figure 7C. Several mecha-
nisms might account for the observed increase inex vivo and/or in vitro expression of CD80/CD86. For
instance, (1) induction of anti-inflammatory type I IFN,
which upregulates CD80/CD86 [32,33,89], (2) elevation
of proinflammatory IFN-γ levels [17,90] or (3) a deli-
cate cytokine balance regulated by the two types of
IFNs driving the expansion of CD80+/CD86+ lympho-
cytes. HTLV-1 virions infecting pDC are capable of in-
ducing IFN-α production [91]. Accurate quantification
of type I IFN levels ex vivo or in vitro is difficult, given
that they are present close to or below detectable limits.
Although an IFN-inducible signature was recently iden-
tified in HAM/TSP [92], the same report showed no
apparent differences in endogenous type I IFN produc-
tion between HCs, ACs and HAM/TSP patients [92].
However, this predominantly myeloid gene signature
identified in whole blood samples did not include CD80
or CD86, which might indicate a cell type-specific regu-
lation of these molecules. Hence, we investigated the
effect of IFN-α/β in vitro stimulation in lymphocyte
subsets in HCs and HAM/TSP patients. This allowed
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tween both cytokines (IFN-α and IFN-β), which has not
been previously carried out in HAM/TSP. In vivo treat-
ment with IFN-α has shown clinical benefits in HAM/
TSP patients [10,14,15,39,40]. IFN-α studies have mainly
focused on T cell subsets and cytokines, indicating a
decrease in the ratio of CD4:CD8 cells, particularly the
CD4+CD25+ and CD4+CD45RO+ T subsets [93]. Few
studies have addressed the biological and immunoregu-
latory properties of IFN-β in the context of HTLV-1 in-
fection. Nonetheless, the pleiotropic effects of IFN-β
are thought to play a protective role in host mono-
nuclear cells upon in vitro infection [94,95]. In vivo, in
HAM/TSP, the only IFN-β1a trial thus far resulted in
amelioration of motor functions with a corresponding de-
crease in spontaneous lymphoproliferation, tax mRNA
as well as HTLV-1-specific CD8+ cells [15]. However, to
date, no studies have investigated the effect of IFN-α or
IFN-β on B cells in HAM/TSP patients. In contrast,
data on the mechanisms of action of IFN-β in vivo are
abundant in MS [96-98], with IFN-β therapy effectively
upregulating CD86 in monocytes and B cells [33,34,89,99]
while downregulating CD80 in vivo [49] but not
in vitro [33]. This discrepancy might be due to an IFN-
γ-mediated mechanism, since IFN-γ aggravated disease
[72], while IFN-β resulted in clinical benefit [37], and
reduced serum IFN-γ levels [100]. In vitro, IFN-β not
only downregulates IFN-γ [100,101], but also antago-
nizes the effect of IFN-γ upon CD64 [102] and MHC
class II expression [29].
Despite IFN-α and IFN-β engaging the same receptors,
differential outcomes of stimulation can be attributed to
their different affinities and rate constants of interaction
with IFN type I receptor subunits, IFN-α receptor
(IFNAR) 1 and IFNAR2 [107,108], and the differential
use of the beta subunit of IFNAR1 [109]. Recently, de
Weerd et al. provided structural evidence of the specific
binding of IFN-β to IFNAR1 in an IFNAR2-independent
manner [110]. Further, IFN-α and IFN-β lead to differen-
tial downregulation and routing of IFNAR2 [107]. The
tyrosine kinases required for IFNα/β-mediated STAT-1
activation, tyrosine kinase (Tyk) 2 and Janus kinase (Jak)
1, are associated with their substrate type I interferon re-
ceptor chains, IFNAR1 and IFNAR2, respectively [111].
Genetic deletion of Jak1 results in the inability to re-
spond to IFN-α or IFN-β [112]. In contrast, deletion of
Tyk2 causes a complete lack of IFN-α responsiveness
[113], whereas IFN-β can still elicit a limited signaling
response in the absence of Tyk2 [114]. Interestingly,
Tyk2 is also an MS susceptibility gene [115]. Selective
IFN-β-induced activation of Jak1 and higher STAT-1
phosphorylation upon IFN-β vs. IFN-α treatment were
observed [116] in both human myocardial fibroblasts
and vascular endothelial cells [117], and a superiorantiproliferative effect of IFN-β over IFN-α was shown
in Ewing’s sarcoma cells in vitro [118]. Preferential in-
duction of CD86 over CD80 in vivo has been demon-
strated in a mouse model for influenza infection, in
which type I IFN-mediated signals were responsible for
upregulation of CD86 in B cells [119]. In addition, CD86
upregulation in human immunodeficiency virus as well
as simian immunodeficiency virus co-infection of den-
dritic cells in vitro was IFN-β but not IFN-α-dependent
[120]. IFN-β-deficient or interferon type I receptor-
deficient (IFNAR−/−) mice developed more severe EAE,
reinforcing a protective role for type I IFN [121,122].
Similar to our results, a recently identified CD11b+
CD11c+B220+CD21- B cell population was predominant
in female aged and autoimmune disease-prone mice in
response to TLR-7 signaling [123]. Interestingly, regula-
tory B cells secreting IL-10 have been shown to play a
protective role in EAE [124] and MS [125], but the pos-
sible relationship between regulatory B cells and CD80
vs. CD86 B cell expression is still undefined.
Finally, our results encourage future clinical trials with
IFN-β in HAM/TSP and open up avenues to B cell- or
CD80-directed therapies in HAM/TSP. Low numbers of
circulating B cells and a corresponding increase in the T:
B ratio have been previously reported in HAM/TSP pa-
tients [126]. Furukawa et al. observed an ex vivo increase
in phosphatidylserine exposure in B cells of HAM/TSP
patients, which was reversible upon in vitro culture [48].
To date, these have been the only investigations with re-
gard to B cells in HAM/TSP. However, B cell depletion
has provided clinical benefit in rheumatoid arthritis as
well as MS [111-115]. Anti-CD20 therapy depleted acti-
vated B cells in PBMCs and CSF, downregulated proin-
flammatory cytokine responses of CD4+ and CD8+ cells
[127,128], reduced inflammatory brain lesions [129,130],
and lowered CSF T and B cell levels. In addition to anti-
CD20 antibodies, anti-CD80 antibodies might represent
a novel therapeutic option in both HAM/TSP and MS.
Anti-CD80 clinical trials have demonstrated clinical
benefit with no severe adverse effects in both psoriasis
[131] and CD80+ B cell lymphoma [132], providing
proof of concept for in vivo targeting of CD80 in human
disorders.Conclusion
We propose two novel biomarkers for future clinical use
in HAM/TSP: CD80+ B cells positively correlating to
disease severity and CD86+ B cells preferentially induced
by IFN-β. Our results reveal B cellimmunotherapy (with
proven clinical benefit in MS) to be a plausible thera-
peutic alternative in HAM/TSP and also suggest CD80-
directed immunotherapy, unprecedented in both HAM/
TSP and MS.
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Additional file 1: Figure S1. Correlation between CD86:CD80 ratio in
B cells and disease severity. Ratio of the ex vivo levels of CD86 and CD80
in B cells negatively correlated to Kurtzke’s EDSS. (*p = 0.036, Pearson’s
r = − 0.50, both the ratio CD86:80 and EDSS are normally distributed,
n = 18).
Additional file 2: Figure S2. CD80 levels discriminate patients with
impaired mobility in HAM/TSP and MS. (A) Ex vivo CD80+:CD19+ ratio
greater than 0.23 (green filled circle, A) (ROC curve, **p = 0.0010, AUC = 0.96)
differentiate HAM/TSP patients with EDSS greater >4 (n = 10) from
those with EDSS ≤4 (n = 8). (B) Ex vivo levels of CD19+CD80+ cells greater
than 8.4% (green filled circle, B) (ROC curve, *p = 0.023, AUC = 0.85)
differentiate patients with active MS (n = 6) from patients with non-active
MS (n = 10).
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